Open AccessSafety and efficacy of high‐dose methotrexate for osteosarcoma in adolescents compared with young adults
Author(s) -
Wippel Brittany,
Gundle Kenneth R.,
Dang Theresa,
Paxton Jillian,
Bubalo Joseph,
Stork Linda,
Fu Rongwei,
Ryan Christopher W.,
Davis Lara E.
Publication year - 2019
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.1898
Subject(s) - medicine , methotrexate , osteosarcoma , retrospective cohort study , toxicity , surgery , chemotherapy , young adult , population , cisplatin , gastroenterology , pathology , environmental health
Background Doxorubicin, cisplatin, and high‐dose methotrexate (HDMTX) are the backbone of pediatric osteosarcoma treatment. However, due to toxicity concerns and the lack of data regarding efficacy in adults, high‐dose methotrexate is rarely used in the adult population. Methods This single‐center retrospective study examined 33 patients who received HDMTX (12 g/m 2 , maximum 20 g) for the treatment of osteosarcoma at Oregon Health and Science University (OHSU) from 2011 to 2017. Time to serum methotrexate level ≤0.1 µmol/L was the primary outcome. Secondary outcomes included number of HDMTX doses received, methotrexate‐related toxicities, and disease outcomes including histologic response at resection and metastasis‐free survival. Results Median age was 20 years [range 7‐38]; 14 patients ≤18 years old and 19 patients >18 years old. Median time to clearance for patients ≤18 years was 79 hours (range 63‐116) compared to 120 hours (range 77‐315) for patients >18 years ( P < 0.001). No correlation between age and histologic response at resection was observed ( P = 0.50), but there was a significant positive correlation between the number of HDMTX doses received before resection and histologic response ( r = 0.49, P = 0.006). There was no significant difference in metastasis‐free survival between age groups, although a trend toward improved survival was noted for patients who received at least seven doses of HDMTX. Conclusion Age over 18 years correlates with delayed methotrexate clearance and fewer administered doses of methotrexate, without increased toxicity. The potential benefit of HDMTX in young adults with osteosarcoma may outweigh toxicity risks.